Background {#section1-1178626417721676}
==========

Licorice root of the *Glycyrrhiza* plant has been used for medicinal purposes for more than 4000 years.^[@bibr1-1178626417721676]^ The plant is widely used in Asia as herbal medicine, flavoring agent, and sweetener.^[@bibr2-1178626417721676]^ As a medicinal plant, licorice root has been used for menopausal symptoms in women.^[@bibr3-1178626417721676],[@bibr4-1178626417721676]^ The estrogenicity of licorice has been attributed to the presence of phytoestrogens such as glabridin, a prenylated isoflavonoid.^[@bibr5-1178626417721676],[@bibr6-1178626417721676]^

According to Botta et al,^[@bibr7-1178626417721676]^ prenylation of an isoflavonoid modulates its response toward estrogen receptors (ER). In 2000, Tamir et al showed that glabridin expressed ER-dependent growth-promoting effect at 10 to 10 mM and ER binding activity in T47D human breast ductal carcinoma cells with an IC~50~ of 5 mM. The ER binding activity of glabridin was found to be similar to values of other known phytoestrogens, such as genistein, which is 10^4^ lower than that of 17β-E~2~. At the same time, glabridin also had ER-independent antiproliferative activity at concentrations of \>15 mM. Tamir et al^[@bibr6-1178626417721676]^ also showed that glabridin activated creatine kinase (CK) activity in skeletal and cardiovascular tissues while increasing uterine weight of rats displaying the potential of glabridin to bring out the positive effect of 17β-E~2~ in the bone, cardiovascular tissues, and the uterus. This selective ER modulator activity of glabridin showed that it acts as a phytoestrogen and suggested that glabridin may serve as a natural estrogen agonist in preventing the symptoms and diseases associated with estrogen deficiency.

Later studies have shown more similarities between glabridin and 17β-E~2~. In 2004, Somjen et al discovered that both glabridin and 17β-E~2~ stimulated DNA synthesis in human endothelial cells and exhibited biphasic effect on proliferation of human vascular smooth muscle cells. Meanwhile, in animal studies, both glabridin and 17β-E~2~ also stimulated the activity of CK in the aorta and left ventricle of the heart of both intact and ovariectomized female rats.^[@bibr8-1178626417721676]^ Later on, Choi^[@bibr9-1178626417721676]^ discovered that glabridin (1-10 μM) significantly increased alkaline phosphatase (ALP) activity, cell proliferation, collagen content, and osteocalcin secretion in MC3T3-E~1~ osteoblast cells, supporting its use for the prevention of osteoporosis and inflammation in the bone. The increase in ALP activity and collagen was thought to be related to estrogenic effects as they were inhibited by 1 µM tamoxifen.^[@bibr9-1178626417721676]^

In the previous study,^[@bibr10-1178626417721676]^ it was found that glabridin displayed a dose-dependent increase in ALP activity from 1 pM to a maximum induction at 10 µM. At 10 µM, glabridin induced cell proliferation of 25.04 ± 3.33% increase from the untreated control. When treated in combination with 17β-E~2~, synergistic effect was observed and the greatest synergy occurred at the combination treatment of 100 nM glabridin with 1 nM 17β-E~2~ (synergy quotient \[SQ\] of 1.217). At this combination treatment, there was a slight decrease in cell proliferation (16.98 ± 3.76% increase from control) compared with 1 nM 17β-E~2~ (19.67 ± 3.42% increase), although it was not significant. However, when compared with 10 nM 17β-E~2~ (28.79 ± 1.26% increase), the combination treatment of 100 nM glabridin with 1 nM 17β-E2 had a significantly lowered induction of cell proliferation.^[@bibr10-1178626417721676]^ Based on the results from the previous study, 5 different treatments were chosen for further downstream study. The treatments selected were the untreated control, 10 µM glabridin, 100 nM glabridin, 1 nM 17β-E~2~, and the combination treatment of 100 nM glabridin with 1 nM 17β-E~2~. The cells were treated for 72 hours and the RNA was extracted for microarray and quantitative reverse transcription polymerase chain reaction (RT-qPCR) analysis to evaluate on the estrogen responsive genes and possible activities.

Materials and Methods {#section2-1178626417721676}
=====================

Chemicals {#section3-1178626417721676}
---------

Minimum Essential Medium (MEM), 17β-E~2~, and dextran-coated charcoal (DCC) were purchased from Sigma, USA. Fetal bovine serum (FBS), fetal calf serum (FCS), antibiotic-antimycotic, and [l]{.smallcaps}-glutamine were obtained from Gibco, USA. Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12 (DMEM/F-12) was sourced from Nacalai Tesque, Japan. Glabridin was purchased from Wako, Japan. Phosphate-buffered saline was from OXOID, Lenexa, KS, USA. Thiazolyl blue tetrazolium bromide (MTT) was obtained from Amresco, USA. Premarin was obtained from Wyeth Pharmaceuticals, USA. Receptor cofactor assay was purchased from Cosmo Bio Co., Ltd, Japan. All other chemicals were purchased from Merck, Germany.

Cell culture and maintenance of Ishikawa cells {#section4-1178626417721676}
----------------------------------------------

Ishikawa cells (99040201; European Collection of Authenticated Cell Cultures \[ECACC\]), which are human endometrial adenocarcinoma cells, were maintained in MEM supplemented with 10% FBS, 1% antibiotic-antimycotic, and 1% [l]{.smallcaps}-glutamine. Cells were passaged twice weekly. Before 2 days of the start of the experiment, near-confluent cells were changed to an estrogen-free basal medium (EFBM). The EFBM consists of DMEM/F-12 media supplemented with 5% DCC-stripped FCS, 1% antibiotic-antimycotic, and 1% [l]{.smallcaps}-glutamine. After 24 hours, the cells were harvested with 0.25% EDTA-trypsin and seeded in 96-well flat-bottomed microtiter plates, in 100 µL of EFBM per well.

Preparation of test compounds {#section5-1178626417721676}
-----------------------------

All the test compounds were dissolved in ethanol (EtOH) and aliquoted accordingly. Prior to use, the test compounds were diluted appropriately with EFBM until the final concentration of EtOH was at 0.1% (v/v). All test compounds were stored at −20°C.

Treatment {#section6-1178626417721676}
---------

Approximately 1.0 × 10^6^cells was seeded into T-75 flasks in 10 mL of EFBM. After 24 hours, when the cells had attached, the EFBM was replaced with 10 mL of EFBM containing test compounds at the appropriate concentrations. After addition of test compounds, the cells were incubated at 37°C in a 5% CO~2~ incubator for 72 hours. All experimental conditions were assayed in triplicate. The test compounds treated to the cells were as follows: untreated control (MEM with 0.1% EtOH), 10 µM glabridin, 100 nM glabridin, 1 nM 17β-E~2~, and 100 nM glabridin and 1 nM 17β-E~2~. All treatments were performed in triplicate.

RNA extraction {#section7-1178626417721676}
--------------

RNA extraction was performed using the QIAshredder spin column (Qiagen, USA) and RNeasy Mini Kit (Qiagen, USA) as per manufacturer's protocol. The eluted RNA was quantified using DU 730 Life Science UV/Vis Spectrophotometer (Beckman Coulter, USA). Only RNA with an A~260~/A~280~ ratio of 1.9 to 2.1 and A~260~/A~230~ ratio of 1.7 to 2.1 was used for subsequent experiments.^[@bibr11-1178626417721676]^

Deoxyribonuclease treatment {#section8-1178626417721676}
---------------------------

The extracted RNA was subjected to deoxyribonuclease (DNase) treatment using the RapidOut DNA Removal Kit (Thermo Scientific, USA) as per manufacturer's protocol. Briefly, 10 µg of RNA in nuclease-free water was added to 5 μL of 10× DNase buffer with MgCl~2~, 2.5 μL of RNase-free DNase I and adjusted with nuclease-free water up to 50 μL.

Microarray analysis {#section9-1178626417721676}
-------------------

The extracted messenger RNA (mRNA) (250 ng) was converted to complementary DNA (cDNA) using GeneChip 3′ IVT Express Kit (Affymetrix, USA) as per manufacturer's protocol (Affymetrix, USA). Next, antisense RNA (aRNA) amplification was performed using the GeneChip 3′ IVT Express Kit (Affymetrix, USA). After aRNA synthesis, the aRNA was placed on ice and quantified immediately for fragmentation. Hybridization was performed using the GeneChip PrimeView array (Affymetrix, USA) in the Affymetrix GeneChip Hybridization Oven 645 (Affymetrix, USA). After washing and staining, the probe arrays were scanned using the Affymetrix GeneChip Scanner 3000. A total of 3 biologically independent assays were performed.^[@bibr12-1178626417721676]^

Microarray data analysis {#section10-1178626417721676}
------------------------

For the analysis, each probe set was analyzed as an individual entity, based on its Affymetrix ID number (Affy ID), regardless of the multiplicity of probe sets representing any given gene product and were considered as representing an individual gene until the completion of the analysis.^[@bibr12-1178626417721676]^ For analysis of gene expression, GeneSpring GX 12.6.1 Software (Agilent, USA) was used. The microarrays were analyzed via robust multiarray analysis. The normalized probe sets were subjected to analysis of variance, unequal variance (Welch) statistical test, Tukey post hoc with asymptomatic *P* value computation, and Benjamini-Hochberg false discovery rate (FDR) for multiple testing correction. The entity list obtained from the different treatments was then filtered using volcano plots. The statistical test chosen for independent comparison of the treatments with the untreated control was *t* test unpaired unequal variance (Welch) with asymptomatic *P* value computation as well as Benjamini-Hochberg FDR for multiple testing correction. The fold change cutoff was set as 1.5, and the *P* value cutoff was set as .05.

Primer design {#section11-1178626417721676}
-------------

Primers specific for the gene of interest was designed using Primer3 software (<http://biotools.umassmed.edu/bioapps/primer3_www.cgi>). The details of primers designed are listed in [Table S1](http://journals.sagepub.com/doi/suppl/10.1177/1178626417721676) for the genes of interest and [Table S2](http://journals.sagepub.com/doi/suppl/10.1177/1178626417721676) for the candidate reference genes.

Quantitative reverse transcription polymerase chain reaction {#section12-1178626417721676}
------------------------------------------------------------

The mRNA extracted was converted to cDNA using Omniscript Reverse Transcriptase (Qiagen, USA), according to manufacturer's protocol. The RT-qPCR was performed using the qPCRBIO SyGreen Mix Lo-ROX 2X master mix (PCR Biosystems, UK) following manufacturer's protocol and conditions, as shown in [Table S3](http://journals.sagepub.com/doi/suppl/10.1177/1178626417721676). All experiments were performed using a Mastercycler RealPlex (Eppendorf, USA). No RT and no DNA template control were included to ensure that the samples were not contaminated with either genomic DNA or primer dimers. All RT-qPCRs were run in triplicate.

RT-qPCR data analysis {#section13-1178626417721676}
---------------------

Quantification cycle (Cq) values for all the genes from all the samples were compiled and imported to qbase^PLUS^ data analysis software (Biogazelle, Belgium). Each gene was adjusted for amplification efficiency according to their own standard curve and was scaled to the untreated control. The lower and upper boundaries of Cq range for positive controls were 5 and 35, respectively. The acceptable replicate variability (difference in Cq) was \<0.5. For normalization, the genes of interest were normalized with the 2 reference genes that were chosen from 8 different housekeeping genes. For statistical analysis, unpaired *t* test was performed with multiple correction testing on the RT-qPCR data after normalization with the reference genes.

Selection of a suitable reference gene {#section14-1178626417721676}
--------------------------------------

The Cq values collected across all samples were used to evaluate the stability of the candidate reference genes. Several programs were used for the identification of suitable reference genes used in this study^[@bibr13-1178626417721676]^: (1) BestKeeper^[@bibr14-1178626417721676]^ (<http://www.gene-quantification.com/bestkeeper.html>), (2) NormFinder^[@bibr15-1178626417721676]^ (<http://moma.dk/normfinder-software>), and (3) geNorm^[@bibr16-1178626417721676]^ in qbase^PLUS^ (Biogazelle, Belgium). The suitable reference genes were selected based on the results generated from all 3 programs.

Results and Discussions {#section15-1178626417721676}
=======================

Microarray analysis showed that the treatment of 10 µM glabridin was relatively similar to 1 nM 17β-E2 {#section16-1178626417721676}
------------------------------------------------------------------------------------------------------

Based on the results from ALP and MTT assay from a previous study,^[@bibr10-1178626417721676]^ glabridin exhibited weak estrogenic activity by increasing ALP activity and it also increased cell proliferation. However, in the presence of 17β-E~2~, the activity of glabridin differed from other isoflavones in that it decreased cell proliferation while increasing ALP activity. The presence of synergism suggests that mechanisms of action of glabridin and 17β-E~2~ are likely to occur at different sites and/or through different pathways. As this is the first study to investigate the use of glabridin and 17β-E~2~ as an estrogen replacement therapy (ERT) agent, additional work is required to determine the activities of each of the drugs alone before activities of their synergistic effects can be determined.^[@bibr17-1178626417721676]^ Hence, microarray was used to study the mechanisms and therapeutic effects exhibited by glabridin and the combination treatment in comparison with 17β-E~2~. Five different treatments were chosen for further downstream study via microarray. The treatments selected were the untreated control, concentration of glabridin which induced the highest estrogenic activity (10 µM glabridin), and the combination treatment of 100 nM glabridin with 1 nM 17β-E~2~ which induces a synergistic increase in estrogenic activity (SQ = 1.217) but with a lower induction of cell proliferation as compared with 17β-E~2~ alone, 100 nM glabridin, and 1 nM 17β-E~2.~ The cells were treated for 72 hours and the RNAs were extracted for microarray and RT-qPCR analyses. All RNA samples had an RNA integrity number greater than 9.4 ([Figure S1](http://journals.sagepub.com/doi/suppl/10.1177/1178626417721676)).

The principal component analysis plot ([Figure 1](#fig1-1178626417721676){ref-type="fig"}) shows that most of the replicates were strongly correlated with each other. Replicates in each of the treatment groups clustered together and away from other treatments, except for 100 nM glabridin which seemed closely correlated with the control. The heat map ([Figure 2](#fig2-1178626417721676){ref-type="fig"}) suggests that the overall gene expression profile of 10 µM glabridin was similar to 1 nM 17β-E~2~, whereas 100 nM glabridin was similar to the control. Displaying similar activities as 17β-E~2~ suggests that glabridin could exert similar activities as 17β-E~2~. This supports many of the past studies which have suggested that glabridin displayed similar effects to 17β-E~2~.^[@bibr6-1178626417721676],[@bibr8-1178626417721676],[@bibr9-1178626417721676],[@bibr18-1178626417721676]^

![Principal component analysis plot of the 5 different treatment groups: 1 nM 17β-E~2~, 10 µM glabridin, 100 µM glabridin, control, and the combination treatment of 1 nM 17β-E~2~ and 100 nM glabridin.](10.1177_1178626417721676-fig1){#fig1-1178626417721676}

![Heat map of biological replicates of Affymetrix gene expression profiles from 5 different treatment groups: 1 nM 17β-E~2~, 100 nM glabridin, 10 µM glabridin, control, and the combination treatment of 100 nM glabridin with 1 nM 17β-E~2~.](10.1177_1178626417721676-fig2){#fig2-1178626417721676}

Volcano plot was used to identify the set of genes that were differently regulated from the control cells with the inclusion criteria set as ≥1.5 fold change with a *P* value of ≤.05. The differentially regulated probe sets were deposited in National Center for Biotechnology Information's Gene Expression Omnibus (GEO)^[@bibr19-1178626417721676]^ and are accessible through GEO Series accession number GSE68333 (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE68333>). The volcano plot showed that there was no significant difference in any probe sets between 100 nM glabridin and the control. Among the 49 395 probe sets on the GeneChip PrimeView array, a total of 8204 probe sets were regulated by treatment of glabridin (10 µM and 100 nM), 1 nM 17β-E~2~, and the combination treatment by 100 nM glabridin with 1 nM 17β-E~2~.

HPRT1 and PPIA represent suitable reference gene {#section17-1178626417721676}
------------------------------------------------

For the determination of the most suitable reference genes, geNorm (based in qbase^PLUS^), NormFinder, and BestKeeper were used. Based on geNorm, all the candidate reference genes were stably expressed (average geNorm *M* ≤ 0.2) ([Figure S2](http://journals.sagepub.com/doi/suppl/10.1177/1178626417721676)). The most stable reference gene was *PPIA*, followed by *HPRT1, B2M, GAPDH*, and *RPL13A*. Meanwhile, *HSP90AB1, ACTB*, and *TBP* represented the 3 least stable reference genes. In general, geNorm *V* should be \<0.15. In this study, geNorm *V* was \<0.15 in general, but when comparing a normalization factor based on the 2 or 3 most stable targets with that of 3 or 4 targets, there was not much added value of including an additional reference gene. Therefore, the use of only 2 reference genes was sufficient.

Based on BestKeeper, *PPIA* (*R* = 0.859, *P* = .001) and *HPRT1* (*R* = 0.743, *P* = .002) represent the top 2 most stably expressed reference genes based on the coefficient of correlation (*R*),^[@bibr14-1178626417721676]^ as shown in [Tables S1 and S2](http://journals.sagepub.com/doi/suppl/10.1177/1178626417721676). The most stable reference genes were chosen based on the following 3 criteria: (1) high *R* value, (2) power (x-fold) of lesser than 2, and (3) standard deviation (±Cq) of lesser than 1. According to NormFinder, *PPIA* represents the most stable gene (*M* = 0.003), followed by *HPRT1* (*M* = 0.005), as shown in [Table S3](http://journals.sagepub.com/doi/suppl/10.1177/1178626417721676). Also, the best combination of 2 genes which had the most stable value was *PPIA* and *HPRT1*, with a stability value of 0.003. Based on the results from geNorm (qbase^PLUS^), NormFinder, and BestKeeper, it was concluded that the 2 most suitable reference targets to be used for this study were *HPRT1* and *PPIA*.

Validation of microarray by RT-qPCR {#section18-1178626417721676}
-----------------------------------

To validate the results obtained from the microarray, 12 genes---9 upregulated genes and 3 downregulated genes---were selected to be tested by RT-qPCR. The comparison of the relative expressions of the target genes from microarray and RT-qPCR is tabulated in [Table 1](#table1-1178626417721676){ref-type="table"}. Consistent with the result of the microarray, *PGR* represented the most highly expressed gene and it was expressed more in 1 nM 17β-E~2~ than the combination treatment of 100 nM glabridin with 1 nM 17β-E~2~. As observed in [Table 1](#table1-1178626417721676){ref-type="table"}, the trend of the genes of interest correlated with the microarray data. Hence, it was concluded that the microarray result shown in the study was suitably validated by RT-qPCR.

###### 

Comparison of the relative expressions of the target genes from microarray and quantitative reverse transcription polymerase chain reaction.

![](10.1177_1178626417721676-table1)

  Genes        Microarray   qbase^PLUS^                                   
  ------------ ------------ ------------- -------- ---------- ----------- ----------
  *ALDH3*A1    ---          4.08          ---      \<1.19\>   3.33        \<1.34\>
  ALPPL2       6.79         ---           4.88     6.39       \<1.17\>    \<4.87\>
  *ANPEP*      12.05        1.61          11.2     16.15      \<0.98\>    11.22
  *C-FOS*      ---          −1.58         −2.06    \<1.18\>   \<1.24\>    0.48
  *C-JUN*      ---          ---           −2.17    \<0.88\>   \<0.89\>    0.58
  COL1A2       5.26         1.94          5.59     2.58       \<2.06\>    \<1.94\>
  *DHRS3*      7.83         1.88          6.16     6.92       2.06        8.9
  *ESR1*       1.59         ---           1.56     2.05       \<0.893\>   \<1.81\>
  *HES2*       6.66         1.53          6.85     \<1.89\>   \<0.51\>    6.6
  *NRIP1*      2.96         ---           3.21     3.22       2.23        \<2.48\>
  *PGR*        120.41       8.16          117.95   47.3       5.37        44.86
  *PPARGC1A*   −1.78        −1.61         −1.94    0.47       0.66        0.38

--- represents values that were not available as they either had fold change \<1.5 or the *P* value was \>.05, whereas values in \< \> represent values that were not statistically significant at *P* \< .05.

Upregulation of PGR confirms activation of classical estrogen signaling of glabridin {#section19-1178626417721676}
------------------------------------------------------------------------------------

To further classify the effects of the different treatments that were not regulated by 17β-E~2~, the probe sets were compared via a Venn diagram. The Venn diagram in [Figure 3](#fig3-1178626417721676){ref-type="fig"} shows the probe sets that are overlapping between the different treatments on Ishikawa cells. Among the 38 commonly regulated probe sets ([Figure 3](#fig3-1178626417721676){ref-type="fig"}), *PGR* represents the most upregulated gene. They were significantly involved in gene ontologies such as blood vessel development, multicellular organismal development, multicellular organismal process, developmental process, single-multicellular organism process, positive regulation of cell cycle, and regulation of epithelial cell proliferation. These probe sets were also involved in the pathways of the nuclear receptors and metabolism of steroid hormone pathways. Among the pathways that were regulated, ovarian infertility genes' pathway was the most significantly regulated.

![Venn diagram showing the overlap between probe sets regulated by the different treatments (1 nM 17β-E~2~, 10 µM glabridin, and the combination treatment of 100 nM glabridin with 1 nM 17β-E~2~) on Ishikawa cells.](10.1177_1178626417721676-fig3){#fig3-1178626417721676}

*PGR* which codes for progesterone receptor was the most upregulated gene in all the different treatment groups ([Table 2](#table2-1178626417721676){ref-type="table"}). The increase in *PGR* expression by 17β-E~2~ had been well established in many steroid-sensitive tissues. In Ishikawa cells, the upregulation of *PGR* indicates estrogenic response as past literature showed that 17β-E~2~ upregulates *PGR*, whereas progesterone downregulates it.^[@bibr20-1178626417721676],[@bibr21-1178626417721676]^ The upregulation of *PGR* also represents a marker for estrogen action that can occur via the classical estrogen signaling through ER-α, ER-β or as a result of mechanical stimulation by progesterone.^[@bibr22-1178626417721676],[@bibr23-1178626417721676]^ Similarly, in this study, *PGR* was upregulated a lot higher compared with *ESR1*. The upregulation of *PGR* by the different treatments confirmed that they displayed estrogenic effects in Ishikawa cells via the classical estrogen pathway. This also showed that *PGR* is more suitable as a gene marker for detecting estrogenic activity in Ishikawa cells, compared with *ESR1.*

###### 

A list of the top 10 highly upregulated and downregulated probe sets in Ishikawa cells based on microarray from the different treatments that were significant compared with the control.

![](10.1177_1178626417721676-table2)

  Probe set ID                            Entrez Gene    Gene symbol         Fold change            
  --------------------------------------- -------------- ------------------- ------------- -------- ------
  ***Top 10 upregulated probe sets***                                                               
   11726168_at                            5241           *PGR*               117.95        120.41   8.16
   11755866_a\_at                         10439          *OLFM1*             20.31         20.12    ---
   11717127_a\_at                         290            *ANPEP*             11.20         12.05    ---
   11728894_at                            54626          *HES2*              6.85          6.66     ---
   11724762_a\_at                         64798          *DEPTOR*            6.47          ---      ---
   11716835_a\_at                         9249           *DHRS3*             6.16          7.83     ---
   11721092_a\_at                         7057           *THBS1*             ---           7.53     ---
   11727334_at                            251            *ALPPL2*            ---           6.79     ---
   11726360_a\_at                         218            *ALDH3A1*           ---           ---      4.08
   11754344_s\_at                         81848          *SPRY4*             ---           ---      3.56
  ***Top 10 downregulated probe sets***                                                             
   11746122_s\_at                         9877           *ZC3H11A*           ---           ---      3.82
   11716915_a\_at                         57509          *MTUS1*             ---           ---      3.34
   11755635_s\_at                         728642///984   *CDK11A///CDK11B*   ---           ---      3.14
   11729051_a\_at                         8496           *PPFIBP1*           ---           ---      3.01
   11731416_at                            4719           *NDUFS1*            ---           ---      2.76
   11723403_at                            10891          *PPARGC1A*          1.94          2.97     2.69
   11718964_at                            57532          *NUFIP2*            ---           ---      2.34
   11718603_a\_at                         222166         *C7orf41*           ---           ---      2.29
   11764058_at                            5621           *PRNP*              ---           2.88     ---
   11744091_s\_at                         552889         *ATXN7L3B*          ---           ---      2.28

--- represents values that were not available as they either had fold change \<1.5 or the *P* value was \>.05.

For global functional classifications, functional annotations derived from GeneSpring's Gene Ontology Analysis database were used. [Figure 4](#fig4-1178626417721676){ref-type="fig"} shows the effect of the distribution of the different treatments on biological processes, cellular components, and molecular functions in Ishikawa cells. Focusing on the probe sets regulated, [Tables 2](#table2-1178626417721676){ref-type="table"} and [4](#table4-1178626417721676){ref-type="table"} presented the top 10 most highly upregulated and downregulated probe sets, respectively, by the treatment. *PGR* represents the most highly regulated gene in all treatments. Most of the genes, such as *PGR, ANPEP, OLFM1, HES2*, and *DHRS3*, were similarly regulated in both the combination treatment and 1 nM 17β-E~2~. This could be because their effect was highly influenced by the presence of 1 nM 17β-E~2~. Except for *PGR*, there were no other similarities between the top 10 highly upregulated genes between the 3 different treatments. Meanwhile, most of the most highly downregulated genes were by 10 µM glabridin. *PPARGC1A* was the only most highly downregulated gene that was common to all treatments.

![The gene ontology of the different treatments (1 nM 17β-E~2~, 10 µM glabridin, and the combination treatment of 100 nM glabridin with 1 nM 17β-E~2~) against the untreated control.](10.1177_1178626417721676-fig4){#fig4-1178626417721676}

[Table 3](#table3-1178626417721676){ref-type="table"} tabulates the effect of the different treatments on gene ontologies related to activities in the circulatory, cardiovascular, and vascular systems. These activities had been, in the past, associated with its estrogenic action. As shown in [Table 1](#table1-1178626417721676){ref-type="table"}, the combination treatment significantly regulated the most number of gene ontologies compared with 10 µM glabridin and 1 nM 17β-E~2~. Meanwhile, [Table 4](#table4-1178626417721676){ref-type="table"} shows the regulation of *NRIP1* by the combination treatment and 1 nM 17β-E~2~ alone. This gene was not regulated by 10 µM glabridin. This gene is involved in the estrogen pathway and was one of the genes chosen for validation of microarray.

###### 

Gene ontologies (GO) of 10 µM glabridin, 1 nM 17β-E~2~, and the combination treatment of 100 nM glabridin with 1 nM 17β-E~2~ that have been associated with its estrogenic action.

![](10.1177_1178626417721676-table3)

  GO ID   GO accession   GO term                             10 µM glabridin   Combination of 1 nM 17β-E~2~ and 100 nM glabridin   1 nM 17β-E~2~
  ------- -------------- ----------------------------------- ----------------- --------------------------------------------------- ---------------
  957     GO:0001568     blood vessel development            1.40E−02          1.14E−06                                            2.97E−03
  1269    GO:0001944     vasculature development             2.35E−02          1.95E−06                                            ---
  24971   GO:0048514     blood vessel morphogenesis          ---               4.22E−05                                            ---
  32123   GO:0072358     cardiovascular system development   3.35E−04          1.96E−05                                            1.25E−03
  32124   GO:0072359     circulatory system development      3.35E−04          1.96E−05                                            1.25E−03

###### 

Regulation of *NRIP1* gene by the combination of 100 nM glabridin with 1 nM 17β-E~2~ and 1 nM 17β-E~2~.

![](10.1177_1178626417721676-table4)

  Probe set ID     Combination of 100 nM glabridin with 1 nM 17β-E~2~   1 nM 17β-E~2~   Gene symbol   Entrez Gene                          
  ---------------- ---------------------------------------------------- --------------- ------------- ------------- ------- ---- --------- ------
  11720153_s\_at   .01                                                  3.212           Up            .01           2.960   Up   *NRIP1*   8204

Glabridin at 10 µM displayed similar effect on the estrogen pathway as 1 nM 17β-E~2~ {#section20-1178626417721676}
------------------------------------------------------------------------------------

For the curation of biological pathways of the differentially regulated probe sets, WikiPathways ([www.wikipathways.org](http://www.wikipathways.org)) was used.^[@bibr24-1178626417721676]^ Similar gene expression profiles between 10 µM glabridin and 1 nM 17β-E~2~ as compared with the control suggested that their activities might be analogous. Estrogen pathway is one of the commonly regulated pathways by 10 µM glabridin and 1 nM 17β-E~2~. From [Figure 5](#fig5-1178626417721676){ref-type="fig"}, it could be seen that 10 µM glabridin and 1 nM 17β-E~2~ were clustered close together in comparison with the control, whereas the combination treatment of 100 nM glabridin with 1 nM 17β-E~2~ regulated the genes in a different manner.

![Hierarchical clustering of the estrogen pathway of the different treatments (untreated control, 1 nM 17β-E~2~, 10 µM glabridin, and the combination treatment of 100 nM glabridin with 1 nM 17β-E~2~).](10.1177_1178626417721676-fig5){#fig5-1178626417721676}

Many of the genes are regulated in a similar manner between 10 µM glabridin and 1 nM 17β-E~2~. Based on the gene list---GSE68333, the effect of glabridin and the combination treatment on the estrogen pathway which could be classical, estrogen response element (ERE)--independent genomic, or nongenomic were drawn out in the form of pathways with the regulation of the different genes involved marked accordingly ([Figure 6A](#fig6-1178626417721676){ref-type="fig"} and [B](#fig6-1178626417721676){ref-type="fig"}). Although 10 µM glabridin did not upregulate *ESR1*, in a previous study, we found that glabridin induced a dose-dependent increase in ER-α-SRC-1 and coactivator complex activity.^[@bibr10-1178626417721676]^ Hence, the proposed pathway for estrogenic action of glabridin in Ishikawa cells is shown in [Figure 6A](#fig6-1178626417721676){ref-type="fig"}. Moreover, 10 µM glabridin regulated several downstream effectors that are involved in the classical and ERE-independent pathways,^[@bibr25-1178626417721676]^ which were also regulated by 1 nM 17β-E~2~, such as *SP-1* of the classical pathway and *PGR* which is involved with the ER pathway in general.

![(A) Possible effects of 10 µM glabridin and (B) 100 nM glabridin with 1 nM 17β-E~2~ on the estrogen pathway after 72 hours treatment on Ishikawa cells. The pathways drawn were adapted from ER signaling pathways from WikiPathways^[@bibr47-1178626417721676]^ and Ingenuity Target Explorer.^[@bibr48-1178626417721676]^](10.1177_1178626417721676-fig6){#fig6-1178626417721676}

C-FOS, C-JUN, and NRIP1 might be involved in the decrease in cell proliferation in the combination treatment of glabridin with 17β-E~2~ {#section21-1178626417721676}
---------------------------------------------------------------------------------------------------------------------------------------

Based on a past study,^[@bibr10-1178626417721676]^ the synergistic effect on ALP induction could have occurred via the ER-α-SRC-1 and coactivator. Meanwhile, glabridin and 17β-E~2~ induced dose-dependent increase in both ALP activity and cell proliferation in Ishikawa cells, and the combination study results showed an increase in ALP activity but with a lower induction of cell proliferation. This suggested that glabridin could act in a different manner from 17β-E~2~. Therefore, it was postulated that this difference could be via ER-α--independent mechanisms in Ishikawa cells.^[@bibr10-1178626417721676]^

Compared with the difference in gene expressions, the combination treatment of 100 nM glabridin with 1 nM 17β-E~2~ downregulated genes, such as *C-FOS* and *C-JUN*, which are transcription factors that heterodimerize to form a part of the nuclear activator protein 1 (AP-1) complex that regulates the expression of genes involved in many rapid cellular events such as proliferation, differentiation, and apoptosis apoptosis.^[@bibr26-1178626417721676]^ Although 10 µM glabridin also decreased *C-FOS* expression, the induction of cell proliferation was comparable with that of 17β-E~2~ treatment. This suggests both that *C-FOS* and *C-JUN* have to decrease in expression to reduce the induction of cell proliferation. [Table S4](http://journals.sagepub.com/doi/suppl/10.1177/1178626417721676) shows that *C-JUN* represented the most highly regulated probe set among the probe sets that were differentially regulated by the combination of 1 nM 17β-E~2~ and 100 nM glabridin alone that was not regulated by others. The probe sets that were only regulated by the combination treatment were observed to regulate gene ontologies such as the regulation of cell death and the regulation of programmed cell death ([Table S5](http://journals.sagepub.com/doi/suppl/10.1177/1178626417721676)). Similarly, [Table S6](http://journals.sagepub.com/doi/suppl/10.1177/1178626417721676) also shows that pathways such as regulation of cell death and regulation of programmed cell death were involved.

The microarray result also showed that the combination upregulated *NRIP1* ([Table 4](#table4-1178626417721676){ref-type="table"}), which is a ligand-dependent corepressor for most of the nuclear receptors. *NRIP1* had also been shown to act as a corepressor that specifically antagonizes ER transcription via interaction with AP-1 protein in vivo.^[@bibr27-1178626417721676],[@bibr28-1178626417721676]^ Previously, it had been reported that retinoic acid could inhibit cell proliferation in Ishikawa cells and *NRIP1* represents 1 of the 4 most highly regulated genes that was upregulated.^[@bibr29-1178626417721676]^ Similarly, in a separate study, upregulation of *NRIP1* was found to inhibit the proliferation of microglioma cells.^[@bibr30-1178626417721676]^ Therefore, the downregulation of *C-JUN* and upregulation of *NRIP1* by the combination of 100 nM glabridin with 1 nM 17β-E~2~ might be the cause of the slight decrease in induction of cell proliferation as compared with 1 nM 17β-E~2~. Combining with the previous postulation, it was suggested that the downregulation of *C-FOS, C-JUN* and upregulation of *NRIP1* could have occurred via ER-α--independent mechanisms.

Possible effects of the combination treatment on ovulation {#section22-1178626417721676}
----------------------------------------------------------

[Table 4](#table4-1178626417721676){ref-type="table"} shows that similar to 1 nM 17β-E~2~, the combination treatment of 100 nM glabridin with 1 nM 17β-E~2~ upregulated *NRIP1. NRIP1* plays an important role in the ovary. Expression of *NRIP1* in the ovary is essential for oocyte release from mature follicles during ovulation, but not for luteinization of mature ovarian follicles.^[@bibr31-1178626417721676],[@bibr32-1178626417721676]^ This could highlight the importance of *NRIP1* in female fertility. *NRIP1* was also found to have a role in the maintenance of pregnancy.^[@bibr33-1178626417721676]^ Another gene which was also involved in ovulation from the ovarian follicle is *PGR*.^[@bibr23-1178626417721676]^

The gene ontology analysis also showed that the combination treatment displayed effects on ovulation. Among the different treatments, only the combination treatment had an effect on reproduction and ovulation. Meanwhile, 10 µM glabridin had no effect on both reproduction and ovulation, and 1 nM 17β-E~2~ only regulated ovulation. The gene ontologies related to steroid and developmental activity based on probe sets that were differently regulated in the combination of 100 nM glabridin with 1 nM 17β-E~2~ are shown in [Tables 5](#table5-1178626417721676){ref-type="table"} and [6](#table6-1178626417721676){ref-type="table"}, respectively. Together with the gene analysis, this suggested that there is a possibility of the combination treatment to be explored for using in aiding ovulation.

###### 

Gene ontologies (GO) related to steroid activity based on probe sets that were differently regulated in the combination of 100 nM glabridin with 1 nM 17β-E~2~.

![](10.1177_1178626417721676-table5)

  GO ID   GO accession   GO term                                                *P* value
  ------- -------------- ------------------------------------------------------ -----------
  3       GO:0000003     reproduction                                           .03
  933     GO:0001542     ovulation from ovarian follicle                        .01
  1221    GO:0001890     placenta development                                   .05
  2266    GO:0003006     developmental process involved in reproduction         .02
  2704    GO:0003707     steroid hormone receptor activity                      .03
  5328    GO:0007292     female gamete generation                               .02
  5548    GO:0007548     sex differentiation                                    .02
  6054    GO:0008585     female gonad development                               .03
  7002    GO:0009725     response to hormone stimulus                           1.44E−04
  12453   GO:0022414     reproductive process                                   .02
  12458   GO:0022602     ovulation cycle process                                .03
  13158   GO:0030728     ovulation                                              1.44E−04
  17513   GO:0035239     tube morphogenesis                                     .02
  17568   GO:0035295     tube development                                       .01
  19740   GO:0042698     ovulation cycle                                        .04
  20380   GO:0043401     steroid hormone mediated signaling pathway             .04
  20596   GO:0043627     response to estrogen stimulus                          2.13E−04
  21871   GO:0045137     development of primary sexual characteristics          7.61E−03
  23151   GO:0046545     development of primary female sexual characteristics   .04
  23255   GO:0046660     female sex differentiation                             .04
  25000   GO:0048545     response to steroid hormone stimulus                   1.95E−06
  25047   GO:0048598     embryonic morphogenesis                                .03
  25051   GO:0048608     reproductive structure development                     8.39E−04
  25172   GO:0048732     gland development                                      .02
  28359   GO:0060135     maternal process involved in female pregnancy          .01
  28784   GO:0060562     epithelial tube morphogenesis                          .02
  28966   GO:0060745     mammary gland branching involved in pregnancy          .05
  29392   GO:0061180     mammary gland epithelium development                   .04
  29669   GO:0061458     reproductive system development                        8.39E−04
  37089   GO:2000241     regulation of reproductive process                     .03

###### 

Gene ontologies (GO) related to developmental activity based on probe sets that were differently regulated the combination of 100 nM glabridin with 1 nM 17β-E~2~.

![](10.1177_1178626417721676-table6)

  GO ID   GO accession   GO term                                                                   *P* value
  ------- -------------- ------------------------------------------------------------------------- -----------
  957     GO:0001568     blood vessel development                                                  1.14E−06
  1009    GO:0001655     urogenital system development                                             1.05E−03
  1011    GO:0001657     ureteric bud development                                                  .03
  1153    GO:0001822     kidney development                                                        .05
  1220    GO:0001889     liver development                                                         .03
  1221    GO:0001890     placenta development                                                      .05
  1269    GO:0001944     vasculature development                                                   1.95E−06
  2266    GO:0003006     developmental process involved in reproduction                            .02
  2454    GO:0003205     cardiac chamber development                                               .03
  2480    GO:0003231     cardiac ventricle development                                             .01
  2528    GO:0003279     cardiac septum development                                                1.54E−03
  2529    GO:0003281     ventricular septum development                                            5.38E−04
  5311    GO:0007275     multicellular organismal development                                      3.63E−09
  5416    GO:0007399     nervous system development                                                .02
  5927    GO:0008406     gonad development                                                         4.03E−03
  6054    GO:0008585     female gonad development                                                  .03
  7151    GO:0009888     tissue development                                                        1.05E−03
  14851   GO:0032502     developmental process                                                     4.77E−11
  17568   GO:0035295     tube development                                                          .01
  21705   GO:0044767     single-organism developmental process                                     2.17E−06
  21871   GO:0045137     development of primary sexual characteristics                             7.61E−03
  23151   GO:0046545     development of primary female sexual characteristics                      .04
  24927   GO:0048468     cell development                                                          4.35E−03
  28651   GO:0060429     epithelium development                                                    1.49E−03
  29228   GO:0061008     hepaticobiliary system development                                        .03
  29392   GO:0061180     mammary gland epithelium development                                      .04
  29519   GO:0061307     cardiac neural crest cell differentiation involved in heart development   .05
  29520   GO:0061308     cardiac neural crest cell development involved in heart development       .04
  29669   GO:0061458     reproductive system development                                           8.39E−04
  31770   GO:0072001     renal system development                                                  .01
  31775   GO:0072006     nephron development                                                       .01
  31778   GO:0072009     nephron epithelium development                                            .01
  31840   GO:0072073     kidney epithelium development                                             .04
  31907   GO:0072141     renal interstitial cell development                                       .04
  32123   GO:0072358     cardiovascular system development                                         1.96E−05
  32124   GO:0072359     circulatory system development                                            1.96E−05
  36879   GO:2000026     regulation of multicellular organismal development                        1.99E−04

Possible regulation of glabridin and the combination treatment on cardiovascular, circulatory, and vasculatory development {#section23-1178626417721676}
--------------------------------------------------------------------------------------------------------------------------

Past studies had shown that premenopausal women had lower chances of cardiovascular diseases as compared with menopausal women, and this effect could be reversed with the intake of ERT.^[@bibr34-1178626417721676],[@bibr35-1178626417721676]^ This is as estrogen has a significant impact on heart and vasculature.^[@bibr34-1178626417721676]^ Gene ontology analysis in this study showed that similar to 17β-E~2~, both 10 µM glabridin and the combination treatment regulated genes involved in the vasculature development, cardiovascular, and circulatory systems that had been associated with estrogenic action ([Table 3](#table3-1178626417721676){ref-type="table"}). Meanwhile, the combination treatment of 100 nM glabridin with 1 nM 17β-E~2~ could regulate blood vessel morphogenesis, vasculature development, cardiovascular, and circulatory systems.

This is consistent with a past study by Tamir et al^[@bibr6-1178626417721676]^ which showed that glabridin activated CK activity in skeletal and cardiovascular tissues. This showed that glabridin was capable of exhibiting the positive effects of 17β-E~2~ in cardiovascular tissues. Even in animal studies, glabridin had been shown to stimulate the activity of CK in the aorta and left ventricle of the heart of both intact and ovariectomized female rats.^[@bibr8-1178626417721676]^ Meanwhile, Somjen et al. (2004) also showed that glabridin stimulated DNA synthesis in human endothelial cells and displayed biphasic effect on proliferation of human vascular smooth muscle cells similar to that of 17β-E~2~. The result of this study together with past studies provides evidence that 10 µM glabridin and the combination treatment could bring about the positive effects of 17β-E~2~ in the cardiovascular, circulatory, and vasculature systems.

Possible regulation of glabridin and the combination treatment in improving polycystic ovary syndrome conditions {#section24-1178626417721676}
----------------------------------------------------------------------------------------------------------------

Polycystic ovary syndrome (PCOS) is a condition correlated with molecular defects of insulin signaling pathway at the postreceptor level in tissues such as adipocytes, muscles, and ovary.^[@bibr36-1178626417721676]^ In this study, both 10 µM glabridin and the combination treatment were reported to play a role in regulating the insulin signaling pathway, MAPK signaling pathways, and adipogenesis ([Table 7](#table7-1178626417721676){ref-type="table"}), which are all related to metabolic syndromes and PCOS.^[@bibr37-1178626417721676]^

###### 

Various pathways related to the metabolic syndrome and MAPK pathways that were regulated by the different treatments.

![](10.1177_1178626417721676-table7)

  Pathways                                          10 µM glabridin   Combination of 1 nM 17β-E~2~ and 100 nM glabridin   1 nM 17β-E~2~
  ------------------------------------------------- ----------------- --------------------------------------------------- ---------------
  ***Metabolic syndrome***                                                                                                
  Insulin signaling                                 3.85E−10          .01                                                 1.05E−06
  Adipogenesis                                      4.09E−05          7.24E−03                                            .03
  ***MAPK pathways***                                                                                                     
  MAPK cascade                                      9.19E−05          ---                                                 9.76E−06
  MAPK targets---nuclear events mediated by MAPKs   1.74E−02          2.49E−04                                            ---
  MAPK signaling pathway                            5.53E−06          1.31E−04                                            5.72E−04
  p38 MAPK signaling pathway                        1.17E−02          ---                                                 ---

Besides, this study found that 10 µM glabridin increased *PPARG* expression by 1.562-fold (*P* = .01), thus suggesting that it could help with metabolic disorders by improving insulin sensitivity and increase uptake of glucose by fat cells via the PPARG pathway.^[@bibr38-1178626417721676]^ This was contradictory to a past study where Lee et al^[@bibr39-1178626417721676]^ found that glabridin did not affect the expression of *PPARG* or adipogenesis in adipose tissue of glabridin-treated obese mice. However, in a later study, Ahn et al^[@bibr40-1178626417721676]^ showed that glabridin and glabridin-rich licorice extract effectively inhibited adipogenesis in 3T3-L1 cells and hence were effective anti-obesity agents.

Another past study had suggested that the upregulation of *PPARG* was indicative of its effect in maintaining glucose homeostasis and improving insulin sensitivity.^[@bibr37-1178626417721676]^ In addition, Nelson-Degrave et al^[@bibr41-1178626417721676]^ found that the inactivation of MAPK pathway was implicated in the pathogenesis of excessive ovarian androgen production in PCOS women. Overall, the upregulation of *PPARG* by glabridin together with the regulation of pathways associated with adipogenesis, insulin resistance, and gluconeogenesis, which are metabolic disorders related to PCOS, suggests that further studies on 10 µM glabridin and the combination in these areas could be explored for the improvement of the PCOS-related metabolic syndromes. This is the first study to show that glabridin could regulate pathways related to PCOS and hence suggests the use of glabridin for further study as ERT for patients with PCOS. From this study, it could be observed that although glabridin exhibited a wide array of activities, they seem to be interconnected and results mostly from its ability to act on ER.^[@bibr42-1178626417721676]^

Possible nongenomic signaling of glabridin in Ishikawa cells {#section25-1178626417721676}
------------------------------------------------------------

[Figure 6A](#fig6-1178626417721676){ref-type="fig"} shows that components of the nongenomic estrogen pathway such as *AKT1, MAPK1, SP-1*, ETS domain-containing protein (*ELK-1*), and dual specificity mitogen-activated protein kinase (*MAP2K1*) were upregulated by 1 nM 17β-E~2~ and 10 µM glabridin. [Table 7](#table7-1178626417721676){ref-type="table"} shows the various MAPK pathways regulated by the different treatments. Based on the results, it could be observed that 10 µM glabridin regulated the most number of MAPK pathways. Hence, it is postulated that glabridin could mediate nongenomic signaling via ER-α^[@bibr43-1178626417721676]^ or insulinlike growth factor 1 receptor (*IGF1R*)^[@bibr44-1178626417721676]^ to phophorylate PI3K/AKT and ERK/MAPK pathways. Besides, the nongenomic pathway could also possibly modulate the functions of ER to enhance the classical mechanism of ER action^[@bibr45-1178626417721676]^ suggesting a possibility for the convergence of genomic and nongenomic actions.^[@bibr46-1178626417721676]^

The biphasic effect demonstrated by glabridin in Ishikawa cells suggested that they regulate estrogenic activity and cell proliferation not only through ER in a dose-dependent manner but also through a different molecular mechanism which differs from the ER pathway that modulates estrogenic activities in endometrial cells.^[@bibr6-1178626417721676]^ This proposes that the nongenomic pathway could be looked into to better understand the effect of glabridin in endometrial cells. Moreover, the differences observed between glabridin and 17β-E~2~ suggested that glabridin acts via a different mechanism from that of 17β-E~2~.

Conclusions {#section26-1178626417721676}
===========

The microarray results showed that 10 µM glabridin and the combination treatment of 100 nM glabridin with 1 nM 17β-E~2~ regulated both the genomic and nongenomic estrogen pathways in Ishikawa cells. Based on the results, both 10 µM glabridin and the combination could possibly provide benefits of estrogens in ERT. The combination might be more suitable as an ERT, whereas glabridin could be explored for the improvement of PCOS-related metabolic syndromes.
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